LCZ696
Drug
Novartis Pharma AG
Total Payments
$76,598
Transactions
69
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $38,253 | 43 | 5 |
| 2017 | $38,346 | 26 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,070 | 6 | 56.2% |
| Travel and Lodging | $30,620 | 41 | 40.0% |
| Food and Beverage | $2,909 | 22 | 3.8% |
Top Doctors Receiving Payments for LCZ696
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Cleveland, OH | $20,437 | 26 |
| , MD | Internal Medicine | Philadelphia, PA | $20,310 | 17 |
| , MD | Clinical Cardiac Electrophysiology | Wynnewood, PA | $11,208 | 11 |
| , MD | Cardiovascular Disease | Boston, MA | $8,697 | 11 |
| Milton Packer | — | Dallas, TX | $8,430 | 2 |
| , MD | Cardiovascular Disease | Boston, MA | $7,517 | 2 |
Ad
Manufacturing Companies
- Novartis Pharma AG $76,598
Product Information
- Type Drug
- Total Payments $76,598
- Total Doctors 5
- Transactions 69
About LCZ696
LCZ696 is a drug associated with $76,598 in payments to 5 healthcare providers, recorded across 69 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $38,253 was paid across 43 transactions to 5 doctors.
The most common payment nature for LCZ696 is "Consulting Fee" ($43,070, 56.2% of total).